Abass Alavi

Abass Alavi
Born Tabriz, Iran
Residence United States
Fields Molecular Imaging
Institutions University of Pennsylvania
Department of Radiology
Alma mater Tehran University of Medical Sciences (M.D., 1964)
University of Bologna (Honorary M.D., 2007)
Shiraz University (Honorary Ph.D, 2007)
University of the Sciences (Honorary D.Sc, 2008)
Notable awards Georg Charles de Hevesy Nuclear Pioneer Award (2004)
Benedict Cassen Prize (2012)

Abass Alavi is a physician-scientist specializing in the field of molecular imaging, most notably in the imaging modality of positron emission tomography (PET). In August 1976, he became the first to perform human PET studies of the brain and whole body using the radiotracer [18F]Fluorodeoxyglucose (FDG). Alavi holds the position of Professor of Radiology and Neurology, as well as Director of Research Education in the Department of Radiology at the University of Pennsylvania. Over the course of his career, he has amassed over 1,000 publications and 40,000 citations, earning an h-index of 101.[1]

Early life and education

Alavi received his medical degree from the Tehran University of Medical Sciences in 1964. He began his training in internal medicine at the Albert Einstein Medical Center and the Philadelphia VA Hospital in 1966. Following subspecialization in hematology/oncology at the University of Pennsylvania, Alavi started his education in medical imaging by enrolling in the radiology department at the Harvard-affiliated Beth Israel Deaconess Medical Center. He joined the University of Pennsylvania School of Medicine in 1971 as a research fellow in nuclear medicine, and was soon appointed to the faculty. He currently holds appointments as Professor and Director of Research Education in the Department of Radiology.

Later life and career

Alavi began his work in tomographic imaging under the guidance of Dr. David Kuhl. He and his colleagues at the University of Pennsylvania were pioneers in performing modern tomographic imaging by utilizing single gamma emitting radionuclides (Single Photon Emission Computer Tomography/SPECT). In 1973, he—along with his colleagues Dr. Kuhl and Dr. Martin Reivich—were the first scientists to conceive the idea of labeling deoxyglucose with positron-emitting fluroide (F-18), leading to the development of FDG. In August 1976, Alavi became the first to administer FDG to a human being and acquire tomographic images of the brain and whole body.

Alavi has been associated with the University of Pennsylvania for all of his career, beginning with a fellowship in Nuclear Medicine in 1971-1973. He was promoted to Professor of Radiology in 1982, and served as Chief of the Division of Nuclear Medicine from 1979 to 2006. Since then, he has been the Director of Research Education in the Department of Radiology.

Alavi has performed numerous research studies utilizing FDG since its inception. Furthermore, soon after the introduction of CT in the early '70s and MRI in the early '80s, Alavi has conducted research that combines PET with these imaging modalities. He is an expert in modern imaging techniques and the clinical applications of PET imaging for the detection of cancer and other disorders including dementia, seizures, cardiovascular disease, and infection.

Alavi served as a member and chairman of scientific study sections at the NIH and American Cancer Society. He has contributed over 1,000 publications to the literature, which have garnered approximately 35,000 citations—both records for faculty members at the University of Pennsylvania. He has trained and mentored countless students in modern imaging techniques, and many of his former students and research fellows now occupy leadership positions in medical imaging across the world.

PET

Positron emission tomography (PET) is a medical imaging technique that produces a three-dimensional image of molecular processes in the body. The system detects pairs of gamma rays emitted as a result of the annihilation of positrons emitted from radionuclides (tracers), which are used to label biologically active molecules.

One of the factors most responsible for the acceptance of positron imaging was the development of radiopharmaceuticals. In particular, the development of labeled 2-Fludeoxyglucose (18F) (2FDG) through the collaboration between scientists at the Brookhaven National Laboratory and investigators at the University of Pennsylvania, was a major factor in expanding the scope of PET imaging. The compound was first administered to two normal human volunteers by Alavi in August 1976 at the University of Pennsylvania.

It is now well established that without the introduction of FDG to medicine, the field of molecular imaging with PET would have been confined to major research institutions, precluding its current widespread clinical applications. In addition, FDG has resulted in the exploration of numerous biologically important compounds in research and drug development.

Awards, honors and membership in honorary societies

Alavi is the recipient of many awards and distinctions,[2] among which are the highest distinctions in nuclear medicine: the Georg Charles de Hevesy Nuclear Pioneer Award [3] given by the Society of Nuclear Medicine, the Cassen Prize of the Society of Nuclear Medicine,[4] and honorary degrees from the University of Bologna, the University of the Sciences in Philadelphia and Shiraz University in Iran. The de Hevesy Award from the Society of Nuclear Medicine was given to Alavi for his pioneering work in the development of positron emission tomography.[5] [6]

He is an internationally renowned expert in modern imaging techniques and in the clinical applications of PET imaging for the detection of cancer as well as neurological, cardiovascular, and infectious disorders.

Other appearances

Alavi has been a long-time supporter of educational and research opportunities for students in nuclear medicine. While his name is associated with the Alavi-Mandell Awards,[7] which recognize trainees and young scientists who publish articles as senior authors in the Journal of Nuclear Medicine, he also supports the Pilot Research Grants and the Bradley-Alavi Student Fellowship Awards. Bradley-Alavi Fellows are named in honor of the late Stanley E. Bradley, a professor of medicine at Columbia University College of Physicians and Surgeons and a prominent researcher in the fields of renal physiology and liver disease, and Abass Alavi, M.D., professor of radiology and chief of the division of nuclear medicine at the University of Pennsylvania Medical Center.[8] funded by the Education and Research Foundation of the Society of Nuclear Medicine.

References

  1. ↑ Abass Alavi's publications indexed by Google Scholar, a service provided by Google
  2. ↑ "2006 Mentor-of-the-Year Award Winner, Abass Alavi, MD". Acnmonline.org. Retrieved 2012-12-26.
  3. ↑ "University of Pennsylvania Health System: News and Periodicals: News Releases". Uphs.upenn.edu. 2004-06-24. Retrieved 2012-12-26.
  4. ↑ "Abass Alavi, MD, and Steven Larson, MD, Receive 2012 Benedict Cassen Prize for Research in Nuclear Medicine". Snm.org. 2012-06-11. Retrieved 2012-12-26.
  5. ↑ Alavi Achievements Recognized with de Hevesy Award SNMjournals (pdf)
  6. ↑ Abass Alavi Awarded the 2004 de Hevesy Award
  7. ↑ http://www-hsc.usc.edu/~jadvar/jnmnews900.pdf
  8. ↑ "SNM Awards $15,000 for 2006 Fellowships in Support of Clinical, Basic Research in Molecular/Nuclear Imaging". Interactive.snm.org. 2006-02-22. Retrieved 2012-12-26.

External links

This article is issued from Wikipedia - version of the Friday, February 12, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.